ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Consumer Non-Durables

Japan Tobacco Inc.

  • 2,505.50 JPY
  • -10.00
  • -0.40%
  • Japan
    Jun 24, 2019
  • Ticker
    TKS(2914)
  • Prev. close
    2,515.5
  • Market cap (JPY)
    5,031.00B
  • Market cap (USD)
    46,867.58M
  • Shares
    2,000M

Business Summary

Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following segments: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, Processed Food, and Other. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The Other segment includes real estate and the handling of corporate expenses relating to corporate communication and operation of the head office. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2018 JPYUSD
Revenue2,215.96B20,064.33M
Gross Profit1,195.57B10,825.28M
Operating income532,832M4,824.50M
Income before tax531,486M4,812.31M
Net income385,676M3,492.08M
EBITDA690,929M6,255.98M
Diluted EPS215.201.94
Dividends Per Share1501.35
Total Assets5,461.40B49,778.06M
Total liabilities2,760.95B25,164.79M
Total equity2,630.59B23,976.61M
Operating cash flow461,389M4,177.62M
Currency in JPYCurrency in USD

Historical Data

 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 2,871.95B 2,252.88B 2,143.28B 2,139.65B 2,215.96B
Gross Profit 1,607.49B 1,267.68B 1,192.41B 1,215.36B 1,195.57B
Operating income 743,190.14M 591,831M 535,001M 526,027M 532,832M
Income before tax 659,314.35M 558,732M 571,748M 538,532M 531,486M
Net income 483,890.79M 398,454M 421,695M 392,409M 385,676M
EBITDA 904,732.40M 730,032M 675,146M 670,864M 690,929M
Diluted EPS 279.19 270.37 235.33 218.97 215.20
Dividends Per Share 100 118 130 140 150
Total Assets 4,704.70B 4,558.23B 4,744.37B 5,221.48B 5,461.40B
Total liabilities 2,082.20B 2,036.71B 2,216.33B 2,379.45B 2,760.95B
Total equity 2,536.83B 2,451.59B 2,456.09B 2,761.68B 2,630.59B
Operating cash flow 543,696M 468,432M 376,549M 419,212M 461,389M
 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 27,132.29M 18,608.90M 19,724.90M 19,081.27M 20,064.33M
Gross Profit 15,186.54M 10,471.12M 10,973.92M 10,838.55M 10,825.28M
Operating income 7,021.16M 4,888.54M 4,923.67M 4,691.07M 4,824.50M
Income before tax 6,228.76M 4,615.14M 5,261.86M 4,802.58M 4,812.31M
Net income 4,571.47M 3,291.24M 3,880.90M 3,499.47M 3,492.08M
EBITDA 8,547.30M 6,030.09M 6,213.44M 5,982.71M 6,255.98M
Diluted EPS 2.63 2.23 2.16 1.95 1.94
Dividends Per Share 0.94 0.97 1.19 1.24 1.35
Total Assets 39,240.21M 37,892.14M 40,677.10M 46,351.38M 49,778.06M
Total liabilities 17,366.88M 16,930.97M 19,002.29M 21,122.55M 25,164.79M
Total equity 21,158.83M 20,379.85M 21,057.92M 24,515.64M 23,976.61M
Operating cash flow 5,136.47M 3,869.26M 3,465.42M 3,738.50M 4,177.62M

Valuation Measures

Dec 2018
PER12.15
ROA7.22%
ROE14.30%
Operating margin24.04%
Profit margin17.40%

Key executives

  • President, CEO & Representative Director: Masamichi Terabatake
  • CFO, Representative Director & Executive VP: Naohiro Minami
  • Executive Officer, Head-Research & Development: Hiroyuki Miki
  • Director, Head-Compliance & General Affairs: Kazuhito Yamashita
  • Representative Director, EVP & Head-Corporate: Kiyohide Hirowatari

Shareholders

  • Government of Japan (33.3%)
  • Japan Tobacco Inc. (11.3%)
  • Nomura Asset Management Co., Ltd. (1.7%)
  • The Vanguard Group, Inc. (1.6%)
  • Mizuho Bank Pension Fund (1.1%)
  • BlackRock Fund Advisors (1.0%)
  • Daiwa Asset Management Co. Ltd. (0.8%)
  • Nikko Asset Management Co., Ltd. (0.8%)
  • Massachusetts Financial Services Co. (0.7%)
  • DWS Investments (UK) Ltd. (0.4%)

Contact Details

  • Website:http://www.jti.co.jp
  • Address: 2-2-1 Toranomon, Minato-Ku, Tokyo, 105-8422, Japan
  • Phone: +81.3.3582.3111

Related Companies

  • JTI Business Services (Asia) Sdn. Bhd.
  • JTI Processadora de Tabaco do Brasil Ltda.
  • United Dhaka Tobacco Co. Ltd.
  • PT Karyadibya Mahardhika
  • PT Surya Mustika Nusantara
  • JT International Financial Services BV
  • Fluxo Brasil Distribuidora de Produtos SA
  • Reynolds American, Inc. /Natural American Cigarettes 9/
  • JTI Tutun Urunleri Sanayi AS
  • JT International Group Holding BV
  • Shanghai JS Foods Co. Ltd.
  • Japan Tobacco (Hong Kong) Ltd.
  • Logic Technology Development LLC
  • JT International Co. Ukraine CJSC
  • JTI Tutun Urunleri Pazarlama AS
  • JT (UK) Ltd.
  • Zandera Ltd.
  • Al Nakhla Tobacco Free Zone SAE
  • Batata SA /Subsdiaries (2)/
  • Al Nakhla Tobacco Co. SAE
  • JT International (Asia Pacific) Ltd.
  • JT International (Philippines), Inc.
  • Haggar Cigarette & Tobacco Factory Ltd. (South Sudan)
  • Haggar Holding Co. /Sudan Cigarette & Tobacco Business (2)/
  • National Tobacco Enterprise (Ethiopia) Share Co.
  • JT International India Pvt Ltd.
  • JT America, Inc.
  • JT International Luxembourg SA
  • JT International Hellas SA
  • JT Financial Service Corp.

Competitors

  • British American Tobacco p.l.c.
  • Imperial Brands PLC
  • Philip Morris International Inc.
  • Altria Group Inc
  • Ajinomoto Co., Inc.
  • Maruha Nichiro Corp.
  • Nichirei Corporation
  • Nissui Pharmaceutical Co., Ltd.
  • Abivax SA
  • British American Tobacco Malaysia Bhd.
  • Electronic Cigarettes International Group Ltd.
  • Pieris Pharmaceuticals, Inc.
  • LT Group, Inc.
  • KT & G Corporation
  • 22nd Century Group, Inc.
  • Akebia Therapeutics, Inc.
  • Swedish Match AB
  • Reata Pharmaceuticals, Inc. Class A
  • FibroGen, Inc.
  • Schweitzer-Mauduit International, Inc.
  • JW Pharmaceutical Corporation
  • NGM Biopharmaceuticals, Inc.
Last Updated on 24 Jun, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media